Rankings
▼
Calendar
AVIR Q2 2025 Earnings — Atea Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena
AVIR
Atea Pharmaceuticals, Inc.
$501M
Q2 2025 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$0
Gross Profit
-$2M
Operating Income
-$41M
Net Income
-$37M
EPS (Diluted)
$-0.44
QoQ Revenue Growth
NaN%
Cash Flow
Operating Cash Flow
-$33M
Free Cash Flow
-$33M
Stock-Based Comp.
$5M
Balance Sheet
Total Assets
$392M
Total Liabilities
$27M
Stockholders' Equity
$364M
Cash & Equivalents
$88M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$0
$0
—
Gross Profit
-$2M
-$104,000
-2226.0%
Operating Income
-$41M
-$47M
+11.9%
Net Income
-$37M
-$41M
+8.3%
← FY 2025
All Quarters
Q3 2025 →